Compound acrivastine sustained release tablets, and preparation method thereof

Abstract

The invention relates to compound acrivastine sustained release tablets, which are prepared from formulated raw materials of, by mass: 14 to 18 parts of acrivastine, 118 to 122 parts of pseudoephedrine hydrochloride, 38 to 42 parts of hydroxypropyl methylcellulose K4M, 18 to 22 parts of hydroxypropyl methylcellulose (100mPa.s), 98 to 102 parts of lactose, 1 to 3 parts of magnesium stearate, and 1to 3 parts of SiO2. The preparation method comprises the steps that: the effective components acrivastine and pseudoephedrine hydrochloride, and the filling material are weighed, sieved and mixed; the framework material hydroxypropyl methylcellulose and an adhesive are added to the mixture; a soft material is prepared and sieved, such that wet granules are prepared; the granules are dried and shaped; a lubricant is added to the granules; all the materials are well mixed and are compressed into tablets according to certain requirements; the tablets are packed, such that finished products are obtained. Compared to common tablets, the sustained release tablets provided by the invention has advantages of long functioning duration, which is 12 hours; mild function; slow release; and less and light adverse reaction.

Description

technical field [0001] The invention relates to the field of medicine preparation, in particular to a compound avastatin sustained-release tablet and a preparation method thereof. Background technique [0002] Avastin is a pyrrole amine antihistamine developed by Glaxo-Wellcome in the UK. Its capsule formulation was first launched in the UK in August 1988 under the trade name Semprex. In 1993, Avastin capsules were approved to go on the market in China, and obtained administrative protection in 1993. In 2001, the administrative protection of this variety was terminated, and its trade name was Xinminle. [0003] Compound Avastin Capsules is a compound preparation of 8 mg of Avastin and 60 mg of pseudoephedrine hydrochloride. The new antihistamine drug Avastin in this product has an anti-allergic effect, while β 2 The receptor agonist pseudoephedrine hydrochloride can quickly relieve nasal congestion and allergic symptoms, so it has an incomparable and obvious advantage. In...

AI Technical Summary

Problems solved by technology

[0005] The weak point of the compound preparation reported at present is that what the compound preparation of Avastin and pseudoephedrine hydrochloride adopts is common preparation, and patient's medicine frequency is many (one day 4-6 time), and patient's tolerance is poor, and bioavailability is low

Images